The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | L | Antineoplastic and immunomodulating agents | |
2 | L04 | Immunosuppressants | |
3 | L04A | Immunosuppressants | |
4 | L04AF | Janus-associated kinase (JAK) inhibitors | |
5 | L04AF03 |
Active Ingredient | Description | |
---|---|---|
Upadacitinib |
Upadacitinib is a selective and reversible JAK inhibitor. In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. It is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients. |
Title | Information Source | Document Type | |
---|---|---|---|
RINVOQ Extended-release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.